In the world of prostate health, the PSA test often sparks debate when used for screening, but its value becomes undeniable once a cancer diagnosis is in place. This blood test, which measures prostate-specific antigen, shifts from a tool of uncertainty to a cornerstone of clinical management, offering crucial insights into disease progression and treatment efficacy.
“Using PSA to monitor cancer progression is one of the most useful tools we have,” says Dr. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor-in-chief of the Harvard Medical School Guide to Prostate Diseases. This perspective highlights a key distinction: while PSA screening in asymptomatic men can lead to overdiagnosis of slow-growing cancers or false alarms from non-cancerous conditions like inflammation or benign enlargement, its application in monitoring established cancer is far more precise and actionable.
For men on active surveillance for low-risk prostate cancer, a rising PSA level can signal the need to transition to treatment. Similarly, in those who have undergone surgery or radiation, regular PSA checks help detect recurrence, guiding next steps in care. However, the interpretation of PSA results varies significantly depending on the initial treatment approach.
Understanding PSA After Prostate Surgery
When a man has his prostate surgically removed, PSA should become undetectable in the blood, as all PSA-producing cells are ideally excised. If follow-up monitoring reveals a rise in PSA, this indicates a biochemical recurrence, meaning cancer cells likely persist somewhere in the body. This early warning allows for timely intervention before symptoms or visible metastases develop.
Interpreting PSA Following Radiation Therapy
Radiation treatments aim to destroy cancer within the prostate while preserving the gland itself. As a result, PSA levels don’t drop to zero but instead decline to a low point called the nadir. Ideally, this nadir should be less than 1 nanogram of PSA per milliliter of blood (ng/mL), with levels below 0.5 ng/mL being preferable. A biochemical recurrence in this context is diagnosed if PSA rises by at least 2 ng/mL above the nadir, signaling potential cancer regrowth.
The Critical Role of PSA Kinetics
Traditionally, after a biochemical recurrence, doctors used bone scans and computed tomography scans of the abdomen and pelvis to search for metastases. If these scans show no evidence of spread, the condition is termed nonmetastatic prostate cancer, where rising PSA reveals cancer that conventional imaging cannot detect. In such cases, the rate of PSA change over time, known as PSA kinetics, becomes a pivotal factor in management decisions.
“If the PSA doubles every few years, then such patients can often be followed without need for specific treatments,” explains Dr. Garnick. “But if the PSA levels double more rapidly, say every six to eight months, then we get concerned.” This example underscores how tracking PSA kinetics helps clinicians assess the aggressiveness of the cancer and determine if additional treatment is warranted.
Advancements in Detection: The Rise of PSMA Imaging
In recent years, a new test has enhanced the ability to locate cancer in men with biochemical recurrence. This involves scanning for prostate-specific membrane antigen (PSMA), a protein found on the surface of most prostate cancer cells. Doctors administer an intravenous tracer that binds to PSMA, and specialized imaging techniques then pinpoint these tagged cells, making them visible like lit matches in a dark room.
PSMA imaging is valuable because it can detect tiny metastases that are too small to be seen with traditional methods, offering a more precise map of disease spread and informing targeted treatment strategies.
PSA as a Gauge for Treatment Efficacy
For men with metastatic prostate cancer, PSA is measured every three months or so to evaluate how well treatments are working. If levels fall or stabilize, it indicates the therapy is effective. Historically, all men with metastatic disease received lifelong treatment, but advancements have changed this paradigm. “Today, long-term treatments can be suspended—sometimes indefinitely—if PSA remains consistently undetectable and the metastases are no longer visible,” notes Dr. Garnick.
PSA also plays a crucial role in assessing experimental therapies for advanced prostate cancer, such as new drugs or combinations not yet FDA-approved. “A significant drop in PSA of 50% or more is considered a positive indicator of treatment response,” Dr. Garnick adds. This metric helps researchers and clinicians gauge the potential of emerging treatments in clinical trials.
In summary, while PSA screening may be fraught with ambiguity, its use in monitoring prostate cancer provides clear, actionable data that guides critical decisions. From detecting recurrence to evaluating treatment success, PSA remains an indispensable tool in the ongoing management of this disease. As Dr. Garnick emphasizes, “PSA monitoring continues to be one of the most important evaluations that physicians and clinicians can perform to determine the best treatments for men with prostate cancer.”
